Avidity
Anaïs Kervadec has a diverse range of work experience in the scientific field. Anaïs is currently employed at Avidity Biosciences, Inc. as a Scientist, a position they have held since April 2021. Prior to this, they worked as a Postdoctoral Associate at Sanford Burnham Prebys Medical Discovery Institute from November 2017 to April 2021. Their doctoral research was conducted at Paris - Centre de Recherche Cardiovasculaire (PARCC), where they evaluated iPS cell-derived beating cardiomyocytes and their secreted extracellular vesicles from October 2014 to September 2017. Before that, they evaluated HUES-derived cardiovascular progenitor cells and their secreted extracellular vesicles at Paris - Centre de Recherche Cardiovasculaire (PARCC), U970 from September 2013 to July 2014. In addition, they gained experience as a vacation laboratory technician at Institut du Thorax - UMR 1087 in July 2013 and as a researcher studying the effect of dexamethasone on T-lymphocyte profile in a mouse model of house dust mites asthma from April 2013 to June 2013. Anaïs also conducted research on the anti-inflammatory potential of quercetin and sesamin on microglial cells activated by MMP+ at UQTR - Université du Québec à Trois-Rivières from April 2011 to June 2011.
Anaïs Kervadec completed their education as follows:
From 2009 to 2011, they attended IUT de Quimper and obtained a DUT in biological engineering, specializing in biological and biochemical analyzes.
In 2011-2012, they pursued their education at UFR Sciences et Techniques de Brest, where they received a Licentiate degree in Health Biology.
The following year, from 2012 to 2013, they attended UFR Sciences et Techniques de Nantes and completed a Master 1 degree in Health Biology.
In 2013-2014, Anaïs studied at Université Paris Cité, where they obtained a Master's degree in Sciences cardiovasculaires.
Finally, from 2014 to 2017, they pursued a Doctor of Philosophy (PhD) at Université Paris Descartes, specializing in Cell/Cellular and Molecular Biology.
In addition to their educational qualifications, Anaïs Kervadec obtained a certification in "From the Laboratory to Leadership" from The Leadership Edge in November 2022.
This person is not in any offices
Avidity
2 followers
Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.